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INTRODUCTION 
Defined as any nausea, retching, or vomiting occurring during 
the first 24 to 48 hours after surgery, postoperative nausea and 
vomiting (PONV) continues to be a significant clinical problem, 
despite decades of searching for more effective antiemetic 
drugs and strategies. The major classes of drugs used for PONV 
prophylaxis include serotonin antagonists, neurokinin-1 re-
ceptor antagonists, corticosteroids, butyrophenones, and phe-
nothiazines.1 One of the most widely used among these drugs 
are serotonin antagonists, namely 5-hydroxytryptamine 3 (5-
HT3) receptor antagonists.2 Ramosetron is a relatively newer 
5-HT3 antagonist with a higher affinity and more prolonged 
activity than previously developed drugs, such as ondansetron 
and granisetron. Even after excluding the retracted papers by 
Mihara, et al.,3 ramosetron was found to have a significant ef-
fect in preventing PONV, compared to placebo, and also the 
Efficacy of Palonosetron vs. Ramosetron 
for the Prevention of Postoperative Nausea and 
Vomiting: A Meta-Analysis of Randomized Controlled 
Trials
Min-Soo Kim1,2, Jin Ha Park1,2, Yong Seon Choi1,2, Sang Hun Park1, and Seokyung Shin1,2
1Department of Anesthesiology and Pain Medicine, Severance Hospital, Seoul;
2Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
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Google Scholar databases (PROSPERO protocol number CRD42015026009). Primary outcomes were the incidences of postopera-
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showed that ramosetron was more effective in reducing POV during the total 48-hr (RR, 3.34; 95% CI, 1.46 to 7.63; p=0.004) and early 
periods (RR, 8.47; 95% CI, 1.57 to 45.72; p=0.013).
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ability to prevent early and late postoperative vomiting (POV) 
better than ondansetron. More recently, a second generation 
5-HT3 antagonist, palonosetron, with greater receptor bind-
ing affinity and a half-life as long as 40 hours, has gained pop-
ularity as an effective anti-emetic. Palonosetron was reported 
to provide better prophylaxis of early and late postoperative 
nausea (PON) and late POV, compared to ondansetron.4
According to the most recent consensus guidelines for PONV 
management that were published in 2014,1 we can employ ei-
ther a risk-adapted approach (e.g., no prevention in low-risk 
patients) or a general multimodal prevention strategy for PONV 
prevention. Regardless of the type of strategy we choose, how-
ever, optimizing a PONV prevention protocol should be based 
on clinical evidence of the characteristics and comparative ef-
ficacies of available drugs. While both palonosetron and ramo-
setron have been reported to be superior to ondansetron for 
PONV prevention,3,4 whether one has better efficacy over the 
other drug is not clear. In light of the increasing importance of 
postdischarge nausea and vomiting (PDNV),5 an antiemetic 
that is effective for durations longer than 24 hours cannot be 
ignored. This meta-analysis was performed to investigate 
whether palonosetron 0.075 mg is superior to ramosetron 0.3 
mg for the prevention of PONV during the first 48 hrs after 
surgery in adult patients.
MATERIALS AND METHODS
This systematic review and meta-analysis included random-
ized controlled trials (RCTs) that included the comparison of 
palonosetron and ramosetron for prevention of PONV after 
surgery under either general or regional anesthesia. Our study 
was conducted in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement,6 and our protocol was registered with PROSPERO 
(CRD420150 26009).
Systematic search and strategy
Two authors (SHP and MSK) independently searched PubMed, 
EMBASE, Web of Science, Cochrane Central Register of Con-
trolled Trials (CENTRAL), KoreaMed, and Google Scholar da-
tabases up to September 29, 2016 without language limitations 
for relevant clinical studies. The search strategy consisted of a 
combination of the following free text words and Medical Sub-
ject Headings (MeSH) terms: “palonosetron”, “ramosetron”, 
“postoperative”, “postanesthetic”, “postanaesthetic”, “nausea”, 
“vomiting”, “emesis”, and “retching”. The following terms were 
used for our search in PubMed: ((((ramosetron) AND (palo-
nosetron)) AND ((((nausea) OR vomiting) OR emesis) OR 
retching)) AND (((((PONV) OR postoperative) OR postanes-
thetic) OR postanaesthetic) OR surgical). Any disagreements 
over inclusion or exclusion of a study were resolved by the 
third author (YSC).
Eligibility criteria
Studies using standard doses of palonosetron 0.075 mg and 
ramosetron 0.3 mg without other adjuncts, such as dexameth-
asone, for prevention of PONV were included in the systemat-
ic review. Study participants were all 18 years or older, under-
going any type of elective surgery involving general or regional 
anesthesia, and administered either palonosetron or ramose-
tron intravenously.
Primary outcome measures were incidence of PON or POV 
during the first 48 hrs after surgery. The first 24 hrs after surgery 
were divided and defined as two different periods: the early 
and late periods (e.g., 0–6 and 6–24 hrs). However, if the first 
24 hrs were divided into three periods, such as 0–2, 2–6, and 
6–24 hrs, the second period was defined as the early period, 
and the third as the late period.4 Also, studies that divided the 
first 24 hrs into three periods, such that the durations of the first 
and second period were relatively too short [e.g., 0 to arrival at 
post-anesthesia care unit (PACU), from arrival to discharge 
from PACU, from discharge from PACU to 24 hr], the first two 
periods were combined and defined as the early period. The 
following 24 hrs after surgery (24–48 hrs) were defined as the 
delayed period, when presented by the authors of each study. 
The entire study period of up to 48 hrs in each study were de-
fined and analyzed as the total period. Study periods beyond 
48 hrs (e.g., 48 to 72 hrs) were not included in the total period. 
PON and POV were evaluated only as categorical data (i.e., yes/
no) and not severity. In studies that presented their data on 
severity scoring scales, the presence of PON or POV was de-
fined as any score above 0. Secondary outcomes were the pro-
portion of participants that showed complete response (CR), 
the proportion of participants that received rescue antiemet-
ics during each study period, and the incidence of common 
adverse effects of the study drugs. 
Nausea was defined as a subjectively unpleasant sensation 
associated with awareness of the urge to vomit, whereas vom-
iting was defined as either vomiting (forceful expulsion of gas-
tric contents from the mouth) or retching (labored, spasmodic, 
rhythmic contraction of the respiratory muscles without the 
expulsion of gastric contents).7 A CR to palonosetron or ramo-
setron was defined as the absence of any nausea or vomiting.
Data extraction
From the final selected studies, the following data were extract-
ed: name of first author, year of publication, country of origin, 
number and characteristics of enrolled participants, type of 
surgery and anesthesia, treatment regimen used for antiemet-
ics and analgesics, and primary and secondary outcomes of 
the present systematic review. When relevant data were pre-
sented in graphical results or were missing from the manu-
script, the authors were contacted via e-mail. 
When the values were presented as median and total range 
or an interquartile range (IQR) of values, the mean value was 
estimated from the devised formula using values of the medi-
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an, low and high end of the range for samples less than 25, and 
the median value itself was regarded as the mean value for 
samples more than 25. The standard deviation was estimated 
from the devised formula using values of the median, low and 
high end of the range for samples less than 15, as the range/4 
for samples from 15 to 70 and as the range/6 for samples great-
er than 70. When only an IQR was provided from selected ar-
ticles, the standard deviation was calculated using IQR/1.35.8,9
Risk of bias in individual studies
Risk of bias in individual studies was evaluated by two authors 
(SS and JHP) according to the Cochrane Collaboration’s tool 
consisting of selection, performance, detection, attrition, and 
reporting and other bias.10 The bias was graded as ‘low risk’, 
‘high risk’, or ‘unclear’. Inter-rater agreement level on risk of 
bias was assessed by running Cohen’s kappa and following the 
guidelines from Landis and Koch.11
Statistical analysis
Stata software (Version 14.0; Stata Corporation, College Station, 
TX, USA) was used to perform the meta-analyses. All statisti-
cal outcomes were presented with 95% confidence intervals 
(CIs). For dichotomous variables, we calculated the relative 
risk (RR) at the individual trial level and the pooled RR using 
the Mantel-Haenszel method in a fixed effects model or the 
DerSimonian-Laird method in a random-effects model. The 
presence of heterogeneity was evaluated with the I2 test. When 
an I2 value more than 50% was observed, heterogeneity was 
regarded as substantial, and the random effect model was ap-
plied. Otherwise, the fixed-effect model was used. Subgroup 
analyses were performed based on number of risk factors, pa-
tient sex, and type of surgery (laparoscopy or spine surgery). 
Visual observation of funnel plots and Egger’s linear regres-
sion test were performed to assess the possibility of publica-
tion bias for outcomes obtained from more than three studies. 
An asymmetric funnel plot and a p value less than 0.10 on Eg-
ger’s test indicated the possible presence of publication bias.
RESULTS
Study selection
Our initial electronic database search yielded 69 citations. Of 
these, 35 were found to be duplications and were excluded. Of 
the remaining studies, 22 were non-relevant to our meta-analy-
sis, and one was a conference abstract. The full text articles were 
retrieved for the remaining 11 studies and were found to fulfill 
our criteria for systematic review and meta-analysis (Fig. 1).12-22
Study characteristics 
A total of 1373 participants were included in the studies ana-
lyzed in this systematic review, of which 685 patients received 
palonosetron 0.075 mg and 688 patients received ramosetron 
0.3 mg intravenously (Table 1). Inhalation anesthesia was per-
formed in 10 studies13-22 and one study used spinal anesthe-
sia.12 Four studies gave antiemetics before induction of anes-
thesia,13,16,17,20 while another four studies gave them at the end of 
surgery.14,15,18,19 The two antiemetics were administered at dif-
ferent time points in the study by Yoon, et al.,21 in which palo-
nosetron was administered just after anesthesia induction 
and ramosetron at the end of surgery. Antiemetics were ad-
ministered twice in the study by Song, et al.,22 which gave the 
study drugs at the end of surgery and at 24 hrs after surgery. 
One study involving cesarean section gave the study drugs af-
ter clamping of the umbilical cord to prevent any possible 
transfer to the fetus.12 Nine of the studies included the 24–48 hr 
period in their study,12-18,21,22 which was defined as the delayed 
period in the present review. Three studies divided the first 24 
hours after surgery into three periods,13,19,20 and therefore, the 
second periods of these studies were defined as the early pe-
riod and data of the first period was not included in the analy-
sis. Three other studies included data for postoperative 48–72 
hr14,17,18 which were not analyzed in the present report. The 
manuscript by Yoon, et al.21 was published in Korean, with an 
abstract available in English. All other papers were in English. 
Risk of bias within studies
The risks of bias are shown in Table 2. All of the studies were 
graded as unclear or low risk regarding random sequence gen-
eration, allocation concealment, incomplete outcome data, se-
lective reporting, and other possible bias. Only the study by Lee, 
et al.15 was graded as high risk in blinding of outcome assess-
ment. Four studies13,16,17,21 lacking description of any conflict of 
interest were graded as unclear in other bias. Cohen’s kappa val-
69 records identified through database searching
(Pubmed=10, EMBASE=28, CENTRAL=10, 
Web of Science=6, KoreaMed=5, 
Google Scholar=10)
34 records screened with titles and abstracts
12 full-text articles assessed for eligibility
11 studies primarily included
11 studies finally included in meta-analysis
69 records after 35 duplicates removed
22 records excluded
Conference poster
 (n=1)
Fig. 1. Flow chart of the literature screening process.
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ue was 0.79 (95% CI, 0.66 to 0.93; p<0.001), suggesting substan-
tial agreement between the two raters that evaluated risk of bias.
Syntheses of results
The results of pooled analyses for PON are summarized in Ta-
ble 3. There was no difference in PON between patients re-
ceiving palonosetron and ramosetron during the total (RR 1.09; 
95% CI, 0.97 to 1.22; I2=16.8%; p=0.135), early (RR, 0.89; 95% 
CI, 0.61 to 1.31; I2=61.5%; p=0.561), late (RR, 0.86; 95% CI, 0.64 
to 1.16; I2=59.9%; p=0.322), and delayed (RR, 1.04; 95% CI, 0.74 
to 1.47; I2=50.3%; p=0.810) periods. Considerable heterogene-
ity was found in the data for early and late PON. No difference 
was seen in PON between groups in subgroup analyses done 
for risk factors, sex, or type of surgery.
Table 2. Summary of the Risk of Bias
Study
Random 
sequence 
generation
Allocation 
concealment
Blinding of 
participant 
and personnel
Blinding of 
outcome 
assessment
Incomplete 
outcome data
Selective 
reporting
Other bias
Swaika, et al.19 Unclear Unclear Unclear Unclear Low risk Unclear Low risk
Piplai, et al.17 Low risk Unclear Low risk Low risk Low risk Low risk Unclear
Park, et al.16 Low risk Low risk Low risk Low risk Low risk Low risk Unclear
Kim, et al.13 Low risk Low risk Low risk Low risk Low risk Low risk Unclear
Roh, et al.18 Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Chattopadhyay and
  Goswami12
Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Lee, et al.15 Low risk Unclear Unclear High risk Low risk Low risk Low risk
Kim, et al.14 Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Yatoo, et al.20 Low risk Unclear Unclear Unclear Low risk Low risk Low risk
Yoon, et al.21 Low risk Unclear Unclear Unclear Low risk Low risk Unclear
Song, et al.22 Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Table 3. Postoperative Nausea
Group or subgroup Number of studies Relative risk (95% CI) I2 (%) p value p in Egger’s test
Total period
Overall analysis 5 1.09 (0.97 to 1.22) 16.8 0.135 0.514
Female 3 1.08 (0.92 to 1.27) 0.0 0.368 0.520
Laparoscopy 2 1.02 (0.85 to 1.22) 0.0 0.873 -
Spine surgery 2 1.12 (0.83 to 1.53)* 74.0 0.457 -
Early period
Overall analysis 10 0.89 (0.61 to 1.31)* 61.5 0.561 0.821
Risk factors† 9 0.99 (0.71 to 1.39)* 50.2 0.971 0.688
Female 7 0.81 (0.43 to 1.52)* 55.3 0.506 0.628
Laparoscopy 6 0.72 (0.33 to 1.57)* 61.1 0.409 0.843
Spine surgery 2 1.13 (0.65 to 1.96)* 84.7 0.673 -
Late period
Overall analysis 10 0.86 (0.64 to 1.16)* 59.9 0.322 0.084
Risk factors† 9 1.02 (0.88 to 1.18) 40.8 0.812 0.152
Female 7 0.70 (0.42 to 1.15)* 70.2 0.154 0.143
Laparoscopy 6 0.74 (0.52 to 1.05) 46.8 0.093 0.370
Spine surgery 2 1.12 (0.91 to 1.37) 0.0 0.274 -
Delayed period
Overall analysis 9 1.04 (0.74 to 1.47)* 50.3 0.810 0.778
Risk factors† 8 1.08 (0.89 to 1.31) 42.6 0.447 0.700
Female 7 0.97 (0.56 to 1.69)* 56.3 0.911 0.363
Laparoscopy 5 0.91 (0.58 to 1.44) 36.1 0.697 0.369
Spine surgery 2 1.06 (0.70 to 1.61)* 56.3 0.777 -
CI, confidence interval.
*Random effects analysis, †Subgroup analysis after excluding study done only in the patients with four risk factors.
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Table 4 shows pooled analyses for POV. There were three 
studies that did not provide POV data for the three separate 
time periods.13,19,20 Swaika, et al.19 and Yatoo, et al.20 did not pres-
ent delayed POV data, while Kim, et al.13 presented POV data 
of the total period only. The studies by Piplai, et al.,17 Chatto-
padhyay and Goswami,12 and Lee, et al.15 all presented POV 
Table 4. Postoperative Vomiting
Group or subgroup Number of studies Relative risk (95% CI) I2 (%) p value p in Egger’s test
Total period
Overall analysis 6 1.08 (0.56 to 2.08)* 77.4 0.827 0.619
Risk factors† 5 1.34 (0.68 to 2.61)* 73.6 0.396 0.409
Female 4 0.73 (0.38 to 1.41)* 75.7 0.342 0.411
Laparoscopy 3 0.55 (0.27 to 1.12)* 70.1 0.099 0.051
Spine surgery 2 3.34 (1.46 to 7.63) 0.0 0.004 -
Early period
Overall analysis 9 0.85 (0.57 to 1.26) 35.5 0.410 0.291
Female 6 0.60 (0.38 to 0.95) 0.0 0.028 0.711
Laparoscopy 6 0.54 (0.33 to 0.89) 0.0 0.015 0.676
Spine surgery 2 8.47 (1.57 to 45.72) 0.0 0.013 -
Late period
Overall analysis 10 1.07 (0.79 to 1.45) 6.3 0.656 0.484
Female 7 1.03 (0.75 to 1.41) 4.3 0.876 0.550
Laparoscopy 6 0.91 (0.59 to 1.39) 0.0 0.653 0.784
Spine surgery 2 2.71 (0.73 to 10.11) 0.0 0.137 -
Delayed period
Overall analysis 7 0.59 (0.39 to 0.89) 0.0 0.013 0.666
Female 5 0.56 (0.36 to 0.86) 0.0 0.009 0.066
Laparoscopy 3 0.46 (0.23 to 0.94) 0.0 0.033 0.243
Spine surgery 2 1.01 (0.21 to 4.94) 0.0 0.991 -
CI, confidence interval. 
*Random effects analysis, †Subgroup analysis after excluding study done only in the patients with four risk factors.
Fig. 2. Forest plot for postoperative vomiting during the early period according to type of surgery. Results of subgroup analysis for laparoscopies, 
spine surgery and cesarean section (neither a laparoscopy or spine surgery) are shown. RR, relative risk; CI, confidence interval.
Study  Palonosetron Ramosetron %
ID RR (95% CI) Events/Total Events/Total weight
Laparoscopy
Swaika, et al.19 0.82 (0.40 to 1.67) 9/29 11/29 24.15
Piplai, et al.17 0.67 (0.12 to 3.71) 2/30 3/30 6.59
Park, et al.16 0.23 (0.07 to 0.76) 3/50 13/50 28.54
Lee, et al.15 1.00 (0.07 to 15.36) 1/35 1/35 2.20
Kim, et al.14 0.60 (0.15 to 2.36) 3/44 5/44 10.98
Yatoo, et al.20 0.50 (0.10 to 2.53) 2/30 4/30 8.78
Subtotal (I2=0.0%, p=0.619) 0.54 (0.33 to 0.89) 20/218 37/218 81.23
Spine surgery
Roh, et al.18 11.00 (0.62 to 196.28) 5/98 0/98 1.10
Song, et al.22 7/19 (0.90 to 57.73) 7/146 1/150 2.17
Subtotal (I2=0.0%, p=0.814) 8.47 (1.57 to 45.72) 12/244 1/248 3.26
Cesarean delivery
Chattopadhyay and Goswami12 0.84 (0.30 to 2.34) 6/55 7/54 15.51
Subtotal 0.84 (0.30 to 2.34) 6/55 7/54 15.51
Overall (I2=35.5%, p=0.134) 0.85 (0.57 to 1.26) 38/517 45/520 100.00
0.00509 1
Favours palonosetron Favours ramosetron
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data for the early, late, and delayed periods but not for the total 
study period. Because the study by Kim, et al.13 was the only 
study done in high risk patients, subgroup analyses according 
to risk factors were not done for early, late, and delayed POV. 
During the total study period there was no difference in POV 
between palonosetron and ramosetron overall or in subgroup 
analyses for risk factors, sex, and laparoscopies. However, 
subgroup analysis for spine surgery showed that ramosetron 
was significantly more effective than palonosetron in reduc-
ing POV during the total study period (RR, 3.34; 95% CI, 1.46 
to 7.63; I2= 0.0%; p=0.004). While there was no difference in 
POV between the two groups during the late period, signifi-
Fig. 3. Forest plot for postoperative vomiting during the delayed period according to gender. Results of subgroup analysis for studies done only in fe-
males and those conducted in both genders are shown. RR, relative risk; CI, confidence interval.
Study  Palonosetron Ramosetron %
ID RR (95% CI) Events/Total Events/Total weight
Female
Piplai, et al.17 0.50 (0.14 to 1.82) 3/30 6/30 12.85
Park, et al.16 0.20 (0.01 to 4.06) 0/50 2/50 5.35
Chattopadhyay and Goswami12 0.65 (0.37 to 1.15) 14/55 21/54 45.39
Kim, et al.14 0.50 (0.21 to 1.21) 6/44 12/44 25.70
Yoon, et al.21 0.49 (0.05 to 5.36) 1/132 2/130 4.32
Subtotal (I2=0.0%, p=0.931) 0.56 (0.36 to 0.86) 24/311 43/308 93.60
Both genders
Roh, et al.18 1.00 (0.14 to 6.96) 2/98 2/98 4.28
Song, et al.22 1.03 (0.60 to 16.27) 1/146 1/150 2.11
Subtotal (I2=0.0%, p=0.987) 1.01 (0.21 to 4.94) 3/244 3/248 6.40
Overall (I2=0.0%, p=0.972) 0.59 (0.39 to 0.89) 27/555 46/556 100.00
0.005 1
Favours palonosetron Favours ramosetron
20
Table 5. Complete Response
Group or subgroup Number of studies Relative risk (95% CI) I2 (%) p value p in Egger’s test
Total period
Overall analysis 8 0.92 (0.74 to 1.16)* 65.8 0.482 0.989
Risk factors† 7 0.86 (0.76 to 0.98) 19.8 0.023 0.434
Female 6 0.96 (0.71 to 1.30)* 68.3 0.792 0.857
Laparoscopy 5 0.98 (0.63 to 1.50)* 74.0 0.909 0.925
Spine surgery 2 0.84 (0.53 to 1.33)* 77.9 0.449 -
Early period
Overall analysis 8 0.99 (0.91 to 1.08)* 52.2 0.845 0.951
Female 5 1.01 (0.95 to 1.08) 44.1 0.700 0.713
Laparoscopy 4 1.02 (0.86 to 1.21)* 56.5 0.838 0.636
Spine surgery 2 0.92 (0.59 to 1.41)* 86.3 0.688 -
Late period
Overall analysis 8 0.98 (0.90 to 1.07) 21.2 0.681 0.512
Female 5 1.02 (0.90 to 1.15) 35.5 0.789 0.457
Laparoscopy 4 1.05 (0.91 to 1.22) 0.0 0.514 0.990
Spine surgery 2 0.92 (0.79 to 1.07) 0.0 0.275 -
Delayed period
Overall analysis 7 1.00 (0.92 to 1.07) 48.7 0.904 0.021
Female 5 1.03 (0.88 to 1.20)* 58.5 0.731 0.048
Laparoscopy 3 1.03 (0.89 to 1.20) 0.0 0.662 0.940
Spine surgery 2 0.98 (0.81 to 1.17)* 53.6 0.797 -
CI, confidence interval. 
*Random effects analysis, †Subgroup analysis after excluding study done only in the patients with four risk factors.
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cant differences in POV were observed for the early and de-
layed periods. Palonosetron was found to be significantly 
more effective than ramosetron in preventing POV in females 
and laparoscopies during the early (RR, 0.60; 95% CI, 0.38 to 
0.95; I2=0.0%; p=0.028 and RR, 0.54; 95% CI, 0.33 to 0.89; 
I2=0.0%; p=0.015) and delayed (RR, 0.56; 95% CI, 0.36 to 0.86; 
I2=0.0%; p=0.009 and RR, 0.46; 95% CI, 0.23 to 0.94; I2=0.0%; 
p=0.033) periods after surgery (Figs. 2 and 3). Palonosetron 
was also found to be more effective in the overall analyses for 
the delayed period (RR, 0.59; 95% CI, 0.39 to 0.89; I2=0.0%; p= 
0.013). Interestingly, subgroup analysis for spine surgery in the 
early period showed that ramosetron was significantly better 
than palonosetron in reducing POV, with a high RR (RR, 8.47; 
95% CI, 1.57 to 45.72; I2=0.0%; p=0.013) (Fig. 2).
The pooled analyses from studies providing data on CR rates 
are shown in Table 5. There was no overall difference between 
palonosetron and ramosetron on CR over the total study peri-
od. However, when subgroup analyses was conducted after 
excluding one RCT that was conducted only in patients at high 
risk of PONV,13 ramosetron was found to result in higher CR 
than palonosetron (RR, 0.86; 95% CI, 0.76 to 0.98; I2=19.8%; p= 
0.023). In the eight studies that presented CR data for three 
different time periods,12,14,16-18,20-22 no difference was found be-
tween palonosetron and ramosetron in the overall analysis, as 
well as in subgroup analyses for sex and for type of surgery. 
The study by Kim, et al.,13 which was done only in high risk pa-
tients, did not provide CR data for separate time periods and 
was thus not included in the subgroup analyses for early, late, 
and delayed periods.
Results of pooled analyses for rescue antiemetics are shown 
in Table 6, and no difference was found between palonosetron 
and ramosetron with regard to the need for rescue antiemetics 
during the total postoperative period. This was also true for the 
early and delayed periods. However, patients that received 
palonosetron were found to require more rescue antiemetics 
than those that received ramosetron (RR, 1.72; 95% CI, 1.02 to 
2.89; I2=0.0%; p=0.042) during the late period. This difference 
was also seen in female patients during the late period (RR, 
2.22; 95% CI, 1.16 to 4.26; I2=0.0%; p=0.016). Subgroup analysis 
for risk factors was not done for early, late, and delayed periods, 
as the study performed in high risk patients13 did not provide 
data for rescue antiemetics for separate time periods.
The results of pooled analyses for complications are shown 
in Table 7. Among the various side effects that were studied in 
each study, we were able to analyze the data reported for head-
ache, dizziness, and constipation during the total study period, 
and found no difference between palonosetron and ramose-
tron for all three complications.
Table 6. Rescue Antiemetics
Group or subgroup Number of studies Relative risk (95% CI) I2 (%) p value p in Egger’s test
Total period
Overall analysis 7 1.03 (0.72 to 1.48)* 56.3 0.855 0.820
Risk factors† 6 1.16 (0.93 to 1.45) 42.3 0.191 0.518
Female 5 0.94 (0.55 to 1.61)* 65.9 0.824 0.985
Laparoscopy 3 0.80 (0.28 to 2.29)* 72.4 0.676 0.872
Spine surgery 2 1.24 (0.88 to 1.77) 0.0 0.222 -
Early period
Overall analysis 6 1.63 (0.95 to 2.80) 0.0 0.079 0.330
Female 4 1.74 (0.90 to 3.40) 0.0 0.103 0.285
Laparoscopy 4 1.46 (0.71 to 2.97) 0.0 0.303 0.513
Late period
Overall analysis 6 1.72 (1.02 to 2.89) 0.0 0.042 0.891
Female 4 2.22 (1.16 to 4.26) 0.0 0.016 0.066
Laparoscopy 4 2.14 (0.62 to 7.47) 0.0 0.231 0.650
Delayed period
Overall analysis 3 1.18 (0.62 to 2.24) 0.0 0.610 0.421
Female 2 0.89 (0.37 to 2.13) 0.0 0.797 -
CI, confidence interval. 
*Random effects analysis, †Subanalysis after excluding study done only in high risk patients.
Table 7. Complications
Complication Number of studies Relative risk (95% CI) I2 (%) p value p in Egger’s test
Headache 5 1.42 (0.97 to 2.06) 0.0 0.069 0.820
Dizziness 5 0.89 (0.71 to 1.13) 25.5 0.330 0.896
Constipation 3 1.70 (0.90 to 3.22) 0.0 0.102 0.593
CI, confidence interval.
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DISCUSSION
There have been recent previous meta-analyses comparing ei-
ther palonosetron4 or ramosetron3,23 with ondansetron, but a di-
rect comparison between each other has not yet been made. 
Xiong, et al.4 reported that palonosetron provides better prophy-
laxis against early PON (0–6 hr), late PON (6–24 hr), and late 
POV (6–24 hr), compared to ondansetron. However, this analy-
sis did not provide data for time periods after 24 hrs. Gao, et al.23 
found ramosetron to be more effective than ondansetron for 
prophylaxis of POV at 0–24 hrs with fewer side effects, but not at 
24–48 hrs. We compared palonosetron with ramosetron up to 48 
hrs after surgery in the present meta-analysis, and although it is 
difficult to draw a definite conclusion with regards to the superi-
ority of one drug over the other, it seems that palonosetron is 
more effective that ramosetron for the prevention of POV at 
postoperative 24–48 hrs. This effect was also seen in females and 
after laparoscopies during the first 6 hours after surgery and 24–
48 hours. However, these findings were reversed in the subgroup 
of patients undergoing spine surgery, where ramosetron was 
found to be more effective in preventing POV. Also, prophylaxis 
with ramosetron was found to require less rescue antiemetics 
than palonosetron at 6–24 hours after surgery.
The concept of PONV after discharge, namely PDNV, has 
grown in importance. The latest guidelines for the management 
of PONV1 have added a new validated simplified risk score for 
PDNV in adults, underlining its significance. The current meta-
analysis included three different periods, the last one being the 
“delayed period”, defined as 24 to 48 hrs after surgery. This peri-
od should be considered an important time frame, as patients 
will still present with significant nausea and vomiting in roughly 
30%.24 The results of our study show that palonosetron was 
more effective in reducing POV than ramosetron during the 
delayed period overall, as well as in females and after laparo-
scopic surgery. This is probably due to the longer half-life and 
receptor binding characteristics of palonosetron,25-27 and may 
imply an advantage of its use over ramosetron for patients un-
dergoing ambulatory surgery. Palonosetron was also found to 
be advantageous in females and in laparoscopies during the 
early period, compared to ramosetron.
An interesting finding of the current analysis was the results 
of subgroup analysis of POV for the total period and early pe-
riod. As mentioned above, palonosetron was found to be bet-
ter than ramosetron in preventing POV in females and lapa-
roscopies during the early and delayed periods. However, the 
results were the opposite in the subgroup analysis for spine 
surgery, which showed better POV prevention with ramose-
tron during the total and early periods. The reason of these 
conflicting results between types of surgery is not clear. Post-
operative pain is known to prolong gastric-emptying time, 
which may contribute to emesis after surgery. Moreover, pain 
of pelvic or visceral origin has been suggested as a significant 
cause of PONV.28 Although palonosetron and ramosetron are 
both 5-HT3 receptor antagonists, palonosetron is structurally 
distinct from first-generation drugs and exhibits allosteric 
binding and positive cooperativity.29 However, whether palo-
nosetron has greater efficacy after abdominal or pelvic sur-
gery is not known and cannot be judged from the present anal-
ysis. With the exception of the study done by Yatoo, et al.,20 the 
remaining six studies done in laparoscopies13-17,19 were also all 
conducted in females, which resulted in a great overlapping 
between the two subgroups. It should also be taken into account 
that, in contrast to the overwhelming majority of females in 
laparoscopy studies, males and females were enrolled at a simi-
lar ratio in spine surgery studies. 
Unlike the results of POV, our analysis was not able to find 
any difference in PON in any of the postoperative periods or 
subgroups. While POV is generally assessed as a dichotomous 
variable of yes or no, PON can be assessed according to severity 
on a Visual Analogue Scale or a Likert-scale, such as mild-mod-
erate-severe. This method of assessment is significant in that 
while ‘mild nausea’ may not require any rescue antiemetics, 
moderate to severe nausea often does and, therefore, would be 
more relevant to clinical practice from the patient’s perspective. 
As the majority of the studies that were included in our present 
analysis presented their results as yes or no variables, our re-
sults were also analyzed and presented in the same manner. 
However, the lack of difference in PON between the two drugs 
may be partially attributable to assessing and analyzing nausea 
as incidence rather than on a quantitative scale.
Among the analyzed studies, one was conducted only in pa-
tients with four risk factors for PONV,13 which can be defined 
as high risk adult patients with an 80% risk for PONV.1 All of 
the patients enrolled in this study were female non-smokers 
with a history of motion sickness or PONV, and also received 
postoperative opioids.13 It is noteworthy that the significant 
difference in CR rates between palonosetron and ramosetron 
can be observed only when this aforementioned study done 
in high risk patients was excluded from analysis (RR, 0.86; 95% 
CI, 0.76 to 0.98; I2=19.8%; p=0.023) (Table 5). Although the pro-
portion of high risk patients included in the other 10 studies 
are not known, it seems that the ability of a single 5-HT3 an-
tagonist to lead to complete absence of nausea and vomiting 
is dampened when the percentage of high risk patients gets 
bigger. It is clear that the antiemetic effects of palonosetron or 
ramosetron, or any other drug for that matter, is not strong 
enough on its own when used alone in patients at high risk of 
PONV. Prophylaxis with combination therapy or a multimodal 
approach including two or more interventions is recommend-
ed in patients at high risk of PONV,1 and therefore, a single an-
tiemetic may not have been effective enough to elicit a differ-
ence in CR rates between the two groups. Considering the latest 
consensus guidelines for the management of PONV,1 a more 
realistic clinical trial would be to study the antiemetic effects 
of 5-HT3 antagonists as part of a multimodal prevention meth-
od in high risk patients receiving at least one other prophylac-
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tic intervention or drug. The fact that ramosetron was found 
to result in a higher CR rate in a patient population with het-
erogenic risk for PONV is in itself inconclusive. 
In terms of adverse events related to the administration palo-
nosetron or ramosetron, four studies failed to present any rele-
vant data,14,15,19,20 although three of these studies14,15,20 comment-
ed that there were no differences between groups with regards 
to headache and dizziness. While there was a considerable dif-
ference in the adverse events that were evaluated in each study, 
the most commonly noted complications were headache, diz-
ziness, and constipation. Our analyses found no difference in 
the incidence of these three adverse effects between palonose-
tron and ramosetron. However, due to the lack of data, it is dif-
ficult to definitely say that a difference in side-effect profile be-
tween palonosetron and ramosetron does not exist. None of 
the studies included in the present meta-analysis reported any 
severe cardiac adverse events, such as QT prolongation or fatal 
arrhythmias, which corresponds to the results of previous stud-
ies that reported the safety of palonosetron and ramosteron on 
the QT interval.30-33
Our meta-analysis has several limitations. Most importantly, 
the numbers of RCTs and patients that were analyzed in our 
study were relatively small. Also, the ethnicity of the patients 
was restricted to Indians and Asians only. Ethnicity may well 
influence the risk of PONV, and there have been reports point-
ing out certain ethnicities to be protective against PONV34 or 
susceptible to motion sickness,35 the latter known as an impor-
tant risk factor of PONV.
As mentioned earlier, aside from one study that was con-
ducted only in high risk patients,13 the baseline risk factors of 
PONV were not consistent between the included trials. Nitrous 
oxide is well known to increase the risk of severe PONV, and a 
recent study suggested that this effect is stronger in Asian pa-
tients.36 Five of the included trials used nitrous oxide with an 
inhalation anesthetic,15,17,19-21 and most of the patients enrolled 
in these trials were Asians. Therefore, the baseline risk of PONV 
may have been higher in these studies, compared to an other-
wise non-biased study population. Also, one study was cond-
ucted in parturients undergoing cesarean section under spinal 
anesthesia, the significance of which is not clear. Although the 
equipotent doses of palonosetron and ramosetron for PONV 
prevention are not known, the generally used doses are 0.075 
mg and 0.3 mg, respectively. Whereas 10 of the studies included 
in the present analysis used these aforementioned doses for 
each drug as a single prophylactic injection either at the begin-
ning or the end of surgery, the study by Song, et al.22 adminis-
tered each drug twice at the end of surgery and 24 hours after 
surgery.
Finally, the definitions of the early and late periods varied 
between the included studies. However, the delayed period as 
defined in the current analysis was identical in all of the nine 
trials that evaluated this time frame, which adds weight to the 
results that show a significantly lower incidence of POV with 
palonosetron during the delayed period. 
In conclusion, the present meta-analysis was not able to re-
veal a definite difference between palonosetron 0.075 mg and 
ramosetron 0.3 mg in the ability to prevent PONV. However, 
subgroup analyses showed that palonosetron was more effec-
tive for the prophylaxis of delayed POV, compared to ramose-
tron, which may be attributed to the longer half-life of palonose-
tron. While palonosetron seems to have an advantage over 
ramosetron in females and patients undergoing laparoscopic 
surgery, ramosetron may be more effective after spine surgery. 
These differences observed in subgroup analyses needs to be 
confirmed by further studies in order to conclude that there is 
an actual difference in the mechanism of action between the 
two anti-emetics. Also, in the light of the increasing importance 
and interest in delayed PONV and PONV after discharge, further 
studies on the prophylactic efficacy and safety of palonosetron 
up to postoperative 72 hrs will help refine PONV protocols for 
ambulatory surgery and patients at risk of prolonged PONV.
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